Abstract:Coherence in the phase of oscillatory neuronal activity indicates functional interaction among brain regions at rest. Infra-slow fluctuations in BOLD signal (band 5 - 0.01 to 0.027 Hz - and band 4 - 0.027 to 0.073 Hz) has been observed using resting state fMRI when employing frequency-domain analysis, and has been previously shown to be altered in schizophrenia. In the current study, we examined the strength and the dynamic variance of phase coherence in these 2 bands (using a sliding window approach) among 6 large-scale brain networks (default-mode, fronto-parietal, salience, sensorimotor, visual, cerebellar) in 129 drug-naïve patients with schizophrenia and 197 healthy controls. Our motivation was to exploit the large-scale resting-state slow-wave oscillatory dynamics to parse the heterogeneity of schizophrenia. Four 6*6 matrices depicting patient vs. control differences in dynamic variance and mean of phase coherence (vPC and mPC respectively) in the slow 4 and slow 5 bands were constructed from resting state fMRI time series obtained from 6 networks based on 160 nodes of Dosenbach’s atlas. Deviations in mean/variance of phase coherence among the 6 networks were identified after FDR correction for each matrix (p<0.05). A latent profile analysis (LPA) was undertaken on the basis of the identified deviant features in the patient group. LPA is a Finite Mixture Modelling approach to identify naturally occurring sub-groups of patients on the basis of multivariable data. The identified subgroups were compared in terms of the severity of clinical symptoms across van der Gaag’s 5 factors of PANSS scale. Patients with schizophrenia showed increased vPC between salience-sensorimotor and visual-cerebellar networks in band 5; decreased vPC between DMN-sensorimotor and DMN-cerebellar networks in band 4. Patients also had a decrease in mPC between DMN-visual and DMN-cerebellar networks in band 5. We were able to identify 3 subgroups of patients using LPA. SZ1 (n=28) and SZ2 (n=45) had higher overall burden of symptoms compared to SZ3 (n=56). SZ2 had the highest burden of negative syndrome score and showed most deviance from healthy controls (5 out of 7 features significantly different from the healthy cohort). SZ1 had the highest burden of positive syndrome scores and had 4 out of 7 features deviant from HC. In contrast, SZ3 had least deviation from HC (3 out of 7 features) and also had less symptom burden across all symptom dimensions. Various abnormalities have been reported in the interactions among the large-scale networks in schizophrenia, with lack of consistency ascribed to syndromic heterogeneity. We illustrate how deviations in time-varying nature of slow-wave oscillations in resting state fMRI can be exploited to meaningfully reduce heterogeneity of this illness. The 3 subgroups thus identified not only show differential symptom burden but also exhibit hierarchical deviation from a normative group of healthy controls (SZ2>SZ1>SZ3>HC). To our knowledge this is the first attempt to stratify ‘neurotypes’ among drug-naïve patients with schizophrenia on the basis of large-scale network dynamics. Given the widespread availability of resting-fMRI data, we anticipate independent replication of our results in the near future.

3.2 Can Neurobiological Subgroups in Psychotic Illness Advantage Drug DISCOVERY?

Neuroimaging biomarkers for drug discovery and development in Schizophrenia

Unraveling NEK4 As a Potential Drug Target in Schizophrenia and Bipolar I Disorder: A Proteomic and Genomic Approach.

Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics

Differentiating Biomarker Features and Familial Characteristics of B-SNIP Psychosis Biotypes

O3.1. NEUROTYPING UNTREATED FIRST EPISODE SCHIZOPHRENIA ON THE BASIS OF SLOW-WAVE RESTING-STATE DYNAMICS

Unveiling Promising Neuroimaging Biomarkers for Schizophrenia Through Clinical and Genetic Perspectives

Subtyping Schizophrenia Patients Based on Patterns of Structural Brain Alterations

Cell-Type Specific Reductions in Interneuron Gene Expression within Subregions of the Anterior and Posterior Cingulate Gyrus of Schizophrenia and Bipolar Disorder Subjects

Predictive Biomarkers for Antipsychotic Treatment Response in Early Phase of Schizophrenia: Multi-Omic Measures Linking Subcortical Covariant Network, Transcriptomic Signatures, and Peripheral Epigenetics

Comparative psychopharmacology of autism and psychotic-affective disorders suggests new targets for treatment

Neurobiology-based Cognitive Biotypes Using Multi-scale Intrinsic Connectivity Networks in Psychotic Disorders

Unveiling Functional Biomarkers in Schizophrenia: Insights from Region of Interest Analysis Using Machine Learning

Linking reduced prefrontal microcircuit inhibition in schizophrenia to EEG biomarkers in silico

Lower Plasma Levels of Selective VGF (Non-Acronymic) Peptides in Bipolar Disorder: Comparative Analysis Reveals Distinct Patterns across Mood Disorders and Healthy Controls

Biomarkers for Psychosis: Are We There Yet? Umbrella Review of 1478 Biomarkers

- Immune biomarkers in psychiatric illness: Findings from the biomarker subgroup of the NSAS Brain-Immune Interactions Workshop

Towards precise resting-state fMRI biomarkers in psychiatry: synthesizing developments in transdiagnostic research, dimensional models of psychopathology, and normative neurodevelopment

Pharmacologic and genetic evidence converge on mechanisms of psychotic illness

Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?

Cognitive subgroups of affective and non-affective psychosis show differences in medication and cortico-subcortical brain networks